Last reviewed · How we verify
Inactive marijuana
At a glance
| Generic name | Inactive marijuana |
|---|---|
| Also known as | inactive cannabis |
| Sponsor | Shanna Babalonis, PhD |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Repeated CBD Administration and Cannabis Outcomes (EARLY_PHASE1)
- Cannabidiol for Reduction of Brain Neuroinflammation (PHASE2)
- Opioid and Cannabinoid Interactions (PHASE1)
- Effects of Core Exercise on Posture and Trunk Endurance in Sedentary Males (NA)
- Varenicline for the Treatment of Cannabis and Tobacco Use Disorders in Veterans (PHASE2)
- Marijuana Effects on Simulated Driving Performance (PHASE1)
- UH3 Varenicline for Cannabis Use Disorder (PHASE2)
- Eye Tracking as a Biomarker of Cannabis Effects (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Inactive marijuana CI brief — competitive landscape report
- Inactive marijuana updates RSS · CI watch RSS
- Shanna Babalonis, PhD portfolio CI